Global Cell and Tissue Culture Supplies Market, By Product Type (Consumables Products (Media (Classical Media, Lysogeny Broth, Chemically Defined Media, Specialty Media, Serum Free Media, and Protein Free Media), Reagents (Growth Factors & Cytokines, Albumin, Amino Acids, Thrombin, Protease Inhibitors, Others), and Sera (Fetal Bovine Serum and Others), Contamination Detection Kits, Cryoprotective Agents), and Instruments (Culture Systems, Biosafety Cabinets, Incubators, Cryostorage Equipment, Roller Bottle Equipment, Pipetting Instruments, and Others)), By Application (Biopharmaceutical Production, Vaccine Production, Drug Screening & Development, Gene Therapy, Toxicity Testing, Cancer Research, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 33.3 Billion in 2023 and is expected to exhibit a CAGR of 12.4 % during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
The strategies by key market players like aquisitions is expected to drive the global cell and tissue culture supplies market growth over the forecast period. For instance, on October 6, 2022, Cytiva Life Sciences IP Holding Corporation, a U.S.-based lifescience company, announced the acquisition of Cevec Pharmaceuticals, a Germany-based biotechnology company, for high-performance cell line development and viral vector manufacturing technologies. With this collaboration, globally more customer will get access to Cevec’s technology and expertise to accelerate and advance in filed of therapeutics.
Global Cell and Tissue Culture Supplies Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others faced problems regarding transportation of drugs from one place to another.
COVID-19 had positive impact on the global cell and tissue culture supplies market due to increasing need for cell and tissue culture techniques for the preparation of vaccines. For instance, according to an article published by Frontiers in Bioengineering and Biotechnology, on August 9, 2022, vaccine supply is a key determinant of vaccination time, especially in low- and middle-income countries. To achieve this vaccine demand, bioreactors can be used. Bioreactors are commonly used for efficient and cost effective vaccine production. They can provide highly process-intensive, optimized viral vaccine product, and optimization of cell culture can also be achieved efficiently.
Global Cell and Tissue Culture Supplies Market: Key Developments
Increasing launch of new range of products that can improve the efficacy of cell culture methods is expected to drive the market growth.
For instance, on June 7, 2022, Evonik Industries AG, a Germany-based specialty chemicals company, launched new peptide, cQrex AC to boost productivity of cell-culture-based biopharmaceuticals. cQrex AC is a chemically defined and highly soluble source of L-cystine that enables the supply of key amino acid to cells. This improves the productivity of monoclonal antibodies, vaccines, viral vectors, and therapeutic cells. It can addresses the challenge of insufficient cystine supply to cells by providing it in sufficient amount to cells. This cQrex is a non-animal-derived and highly pure peptide.
Browse 25 Market Data Tables and 29 Figures spread through 160 Pages and in-depth TOC on Global Cell and Tissue Culture Supplies Market, By Product Type (Consumables Products (Media (Classical Media, Lysogeny Broth, Chemically Defined Media, Specialty Media, Serum Free Media, and Protein Free Media), Reagents (Growth Factors & Cytokines, Albumin, Amino Acids, Thrombin, Protease Inhibitors, Others), and Sera (Fetal Bovine Serum and Others), Contamination Detection Kits, Cryoprotective Agents), and Instruments (Culture Systems, Biosafety Cabinets, Incubators, Cryostorage Equipment, Roller Bottle Equipment, Pipetting Instruments, and Others)), By Application (Biopharmaceutical Production, Vaccine Production, Drug Screening & Development, Gene Therapy, Toxicity Testing, Cancer Research, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/cell-and-tissue-culture-supplies-market-3770
Key Takeaways of the Global Cell and Tissue Culture Supplies Market :
- Global cell and tissue culture supplies market is expected to exhibit a CAGR of 12.4 % during the forecast period. Funding raised by key market players is expected to accelerate its research and development activities. For instance, on February 23, 2022, CellulaRevolution Ltd., a U.K.-based biotechnology company, raised US$ 1.87 million in a funding round to accelerate the launch of its continuous cell culture technology. The funding round was led by Happiness Capital, a China- based venture capital firm, and also included Allusion One, a Belgium based investment firm,. The company plans to use the investment to accelerate research and development, and to take its technology to market.
- Among product type, consumable products segment is expected to dominate the global cell and tissue culture supplies market over the forecast period, owing to launch of new growth medium for effective cell culture techniques. For instance, on May 16, 2023, Lonza Group, a Switzerland-based biotechnology company, launched TheraPEAK T-VIVO cell and culture medium with a novel chemically defined formulation developed to optimize and streamline CAR T-cell manufacturing. Unlike other serum-free media, this medium does not require the addition of human serum or its components to achieve high performance. By eliminating animal components, the medium improves performance, delivers greater consistency and process control, and simplifies regulatory approval for faster time-to-market.
- Among region, North America is expected to be the dominant region in the global cell and tissue culture supplies market, owing to the increasing launches of newer cell tissue culture supplies in the region. For instance, on March 23, 2021, Thermo Fisher Scientific,Inc., a U.S.- based scientific instrumentation company, launched new Gibco Human Plasma-like Medium (HPLM), the first cell culture medium on the market that mimics the metabolic profile of human plasma, and that is designed to provide researchers with a realistic view of cell growth within the human body. It resembles the human body cellular environment by containing the same salt concentrations found in human plasma, as well as the same concentrations of over 60 polar metabolites. When supplemented with fetal bovine serum (FBS), HPLM can support cell growth and viability re comparable to that of conventional basal media formulations supplemented with FBS.
- Major players operating in the global cell and tissue culture supplies market include Becton, Dickinson and Company, Merck KGaA, Corning, Inc., Lonza Group, Eppendorf AG, Thermo Fisher Scientific, Inc., Affymetrix, Inc., GE Healthcare, VWR International, LLC, and WHEATON Industries, Inc.
